Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 1/20 | 0.54 |
| ▸ | DRD4 | P21917 | 5/20 | 0.51 |
| ▸ | DRD2 | P14416 | 3/20 | 0.49 |
| ▸ | DRD3 | P35462 | 3/20 | 0.49 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.49 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.49 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.49 |
| ▸ | HTR1A | P08908 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7256938 | 0.87 | PPARG (0.58) | PPARGDRD4DRD2DRD3ADRA1D | |
| SCHEMBL7244085 | 0.87 | PPARG (0.60) | PPARGDRD4DRD2DRD3ADRA1D | |
| SCHEMBL7256547 | 0.86 | PPARG (0.56) | PPARGDRD4DRD2DRD3ADRA1D | |
| SCHEMBL7252088 | 0.85 | PPARG (0.59) | PPARGDRD4DRD2DRD3ADRA1D | |
| Hydrochloric Acid SCHEMBL7253613 | 0.85 | PPARG (0.55) | PPARGDRD4DRD2DRD3ADRA1D | |
| SCHEMBL7256394 | 0.84 | DRD4 (0.58) | PPARGDRD4DRD2DRD3ADRA1D | |
| SCHEMBL7256017 | 0.83 | DRD4 (0.57) | PPARGDRD4DRD2DRD3ADRA1D | |
| Hydrochloric Acid SCHEMBL7252051 | 0.83 | DRD4 (0.57) | PPARGDRD4DRD2DRD3ADRA1D | |
| SCHEMBL7250601 | 0.83 | PPARG (0.56) | PPARGDRD4DRD2DRD3ADRA1D | |
| SCHEMBL7256249 | 0.83 | PPARG (0.56) | PPARGDRD4DRD2DRD3ADRA1D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030040538-A1 | Novel substituted tricyclic compounds | ASAHI-KASEI KABUSHIKI KAISHA (JP) | 2003-02-27 | — | — | US | claimed |
| US-20030040538-A1 | Novel substituted tricyclic compounds | ASAHI-KASEI KABUSHIKI KAISHA (JP) | 2003-02-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030040538-A1 | Novel substituted tricyclic compounds | CPT1A, CBR1, NR1H3 | PPARG 332/4885DRD4 471/4885DRD2 1040/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.